Pacira Pharmaceuticals (NASDAQ: PCRX) and Marinus Pharmaceuticals (NASDAQ:MRNS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, dividends, earnings and risk.
Valuation & Earnings
This table compares Pacira Pharmaceuticals and Marinus Pharmaceuticals’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Pacira Pharmaceuticals||$276.37 million||6.48||-$37.94 million||($1.31)||-33.70|
|Marinus Pharmaceuticals||N/A||N/A||-$28.64 million||($0.93)||-8.33|
This table compares Pacira Pharmaceuticals and Marinus Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Risk and Volatility
Pacira Pharmaceuticals has a beta of 2.2, suggesting that its share price is 120% more volatile than the S&P 500. Comparatively, Marinus Pharmaceuticals has a beta of 2.44, suggesting that its share price is 144% more volatile than the S&P 500.
Insider and Institutional Ownership
49.8% of Marinus Pharmaceuticals shares are owned by institutional investors. 6.6% of Pacira Pharmaceuticals shares are owned by insiders. Comparatively, 6.4% of Marinus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
This is a breakdown of current ratings and target prices for Pacira Pharmaceuticals and Marinus Pharmaceuticals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Pacira Pharmaceuticals currently has a consensus price target of $49.21, indicating a potential upside of 11.47%. Marinus Pharmaceuticals has a consensus price target of $14.50, indicating a potential upside of 87.10%. Given Marinus Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts clearly believe Marinus Pharmaceuticals is more favorable than Pacira Pharmaceuticals.
Marinus Pharmaceuticals beats Pacira Pharmaceuticals on 8 of the 13 factors compared between the two stocks.
Pacira Pharmaceuticals Company Profile
Pacira Pharmaceuticals, Inc. is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers. Its lead product candidate is EXPAREL (bupivacaine liposome injectable suspension), which consists of bupivacaine, an amide-type local anesthetic, encapsulated in DepoFoam and is indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. In addition to EXPAREL, DepoFoam is also the basis for its other Food and Drug Administration-approved commercial product, DepoCyt(e), which it manufactures for its commercial partners, as well as its product candidates. The Company’s other product candidates include DepoMeloxicam (DepoMLX) and DepoTranexamic Acid (DepoTXA). DepoCyt(e) is indicated for the intrathecal treatment of lymphomatous meningitis.
Marinus Pharmaceuticals Company Profile
Marinus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings. Ganaxolone acts on the GABAA receptor, a target in the brain known for both anti seizure and anti anxiety effects through positive allosteric modulation. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19 pediatric epilepsy.
What are top analysts saying about Pacira Pharmaceuticals? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Pacira Pharmaceuticals and related companies.